相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer
Roy S. Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Palmitoylation of the TRAIL receptor DR4 confers an efficient TRAIL-induced cell death signalling
Aurelie Rossin et al.
BIOCHEMICAL JOURNAL (2009)
Targeting apoptosis: preclinical and early clinical experience with mapatumumab, an agonist monoclonal antibody targeting TRAIL-R1
Patricia Moretto et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Death Receptor 5-Recruited Raft Components Contributes to the Sensitivity of Jurkat Leukemia Cell Lines to TRAIL-induced Cell Death
Yifan Min et al.
IUBMB LIFE (2009)
Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib
Troy A. Luster et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Death receptor-4 (DR4) expression is regulated by transcription factor NF-κB in response to etoposide treatment
Francisco Jose Mendoza et al.
APOPTOSIS (2008)
Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulation
Eun Hee Kim et al.
CANCER RESEARCH (2008)
Upregulation of DR5 by proteasome inhibitors potently sensitizes glioma cells to TRAIL-induced apoptosis
Holger Hetschko et al.
FEBS JOURNAL (2008)
Lysophosphatidic acid protects cancer cells from histone deacetylase (HDAC) inhibitor-induced apoptosis through activation of HDAC
Ganchimeg Ishdorj et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Cholera toxin B accelerates disease progression in lupus-prone mice by promoting lipid raft aggregation
Guo-Min Deng et al.
JOURNAL OF IMMUNOLOGY (2008)
The role of TRAIL death receptors in the treatment of hematological malignancies
Elizabeth S. Henson et al.
LEUKEMIA & LYMPHOMA (2008)
Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer
F. Anthony Greco et al.
LUNG CANCER (2008)
Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers
Ruth Plummer et al.
CLINICAL CANCER RESEARCH (2007)
Lipid rafts and nonrafts mediate tumor necrosis factor-related apoptosis-inducing ligand-induced apoptotic and nonapoptotic signals in non-small cell lung carcinoma cells
Jin H. Song et al.
CANCER RESEARCH (2007)
Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL
Maria Gomez-Benito et al.
EXPERIMENTAL CELL RESEARCH (2007)
Lipid rafts: at a crossroad between cell biology and physics
Ken Jacobson et al.
NATURE CELL BIOLOGY (2007)
Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma
Michelle A. Fanale et al.
DRUGS (2007)
Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2
Delphine Merino et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells
Albert F. Kabore et al.
APOPTOSIS (2006)
Transcription factor NF-κB differentially regulates death receptor 5 expression involving histone deacetylase 1
S Shetty et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1
M MacFarlane et al.
CELL DEATH AND DIFFERENTIATION (2005)
Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts
RL VanOosten et al.
MOLECULAR THERAPY (2005)
Lysophosphatidic acid (LPA) protects primary chronic lymphocytic leukemia cells from apoptosis through LPA receptor activation of the anti-apoptotic protein AKT/PKB
XJ Hu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies
S Inoue et al.
CELL DEATH AND DIFFERENTIATION (2004)
Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells
D Delmas et al.
ONCOGENE (2004)
TNF-related apoptosis-inducing ligand (TRAIL): A potential candidate for combined treatment of hematological malignancies
P Secchiero et al.
CURRENT PHARMACEUTICAL DESIGN (2004)
TRAIL and its receptors as targets for cancer therapy
H Yagita et al.
CANCER SCIENCE (2004)
Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia
JB Johnston et al.
ONCOGENE (2003)
Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway
T Ohtsuka et al.
ONCOGENE (2003)
Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia
M MacFarlane et al.
ONCOGENE (2002)
Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) up-regulates death receptor 5 (DR5) mediated by NFκB activation in epithelial derived cell lines
S Shetty et al.
APOPTOSIS (2002)
Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D
A Olsson et al.
LEUKEMIA (2001)
Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types
XD Zhang et al.
FEBS LETTERS (2000)
Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site
R Takimoto et al.
ONCOGENE (2000)
Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL
SB Gibson et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)